Cardurion logo - click to return to the homepage

Cardurion Pharmaceuticals Presents Positive Clinical Results from CARDINAL‑HF Phase 2a Clinical Trial of PDE9 Inhibitor in Patients With Heart Failure

Burlington, Mass. – May 11, 2024 – Cardurion Pharmaceuticals, Inc. (“Cardurion”), a clinical-stage biotechnology company developing next-generation therapeutics for the treatment of cardiovascular diseases, today announced the presentation of positive clinical data from CARDINAL‑HF, the first Phase 2 proof-of-concept clinical trial of a phosphodiesterase-9(PDE9) inhibitor in patients with heart failure. These data were presented today at […]

This site uses cookies and third-party scripts to provide certain services. View Privacy Policy

Skip to content